A. Oliver Sartor, MD
Professor of Medicine
Medical Director, Tulane Cancer Center
C. E. and Bernadine Laborde Profoessor of Cancer Research
Dr. Sartor received his MD from Tulane University with honors in 1982. After internship at the University of Pennsylvania, he trained in Internal Medicine at Tulane Medical School. After completing fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland in 1989, he served until 1993 as a Senior Investigator at the NCI and began focusing on novel therapeutics for advanced prostate cancer patients.
Dr. Sartor returned to Louisiana in 1993 to serve as an Associate Professor at the LSU Medical School in Shreveport and then moved to the LSU Health Sciences Center in New Orleans in 1998 as the Patricia Powers Strong Professor of Oncology, Stanley S. Scott Cancer Center Director, and Hematology/Oncology Section Chief.
Dr. Sartor was the Co-Director of the Louisiana Cancer Research Consortium, starting at its legislative inception in 2002. In March 2006, he left LSU to join the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and the Harvard Medical School.
In January 2008, Dr. Sartor joined Tulane University as the Piltz Professor of Cancer Research in the Departments of Medicine and Urology.
Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.
Dr. Sartor has published over 100 scholarly articles, is the Medical Oncology Co-Chair of the Radiation Therapy Oncology Group (RTOG) Genitourinary Committee, is the Co-Editor in Chief of the peer-reviewed journal “Clinical Genitourinary Cancer”, and serves as Chairman of the Department of Defense Prostate Cancer Integration Panel in 2008-2009.
Barrisford GW, Sartor O, Richie JP. Solitary Adrenal Metastatic Lesion in a Patient with a History of Prostate Cancer. Clin Genitourin Cancer 2009 Jan; 7(1):64-6.
Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol. 2009 Mar; 181(3):1104-13.
Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009 Mar 1; 115(5):981-7.
Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT. The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer. COMPARE Registry Steering Committee. Urology 2009 Jul 7.
Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC. Cytokine Genetic Polymorphisms and Prostate Cancer Aggressiveness. Carcinogenesis 2009 May 27.
Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res 2009 Jun 1; 15(11):3850-5. Epub 2009 May 19
Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL. Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs? J Clin Oncol 2009 Jul 27.
Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT; COMPARE Registry Steering Committee. The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer. Urology 2009 Jul 7.
Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res 2009 Jun 1; 15(11):3850-5. Epub 2009 May 19.
Sartor O. Decision-making in clinically localized prostate cancer: evaluating and communicating risks. Clin Genitourin Cancer. 2008 Sep;6(2):63-4. Cancer. 2009 Mar 1;115(5):981-7.
Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer The Therapy Assessed by Rising PSA (TARP) study rationale and design. The Canadian Journal of Urology 2009. in press
Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL. A Framework for the Identification of Men at Increased Risk for Prostate Cancer. J Urol. 2009 Sep 14.
1430 Tulane Ave, New Orleans, LA 70112 504-988-5187 email@example.com